文献速递传染病防控与疫情报告卫生政策与健康促进

挪威2020/21年冬季疫苗接种前成人人群SARS-CoV-2抗体血清流行率

Seroprevalence of antibodies against SARS-CoV-2 in the adult population during the pre-vaccination period, Norway, winter 2020/21.
PubMed 文献 · Euro Surveill · 2022-01-01

该研究于2020年11月至12月在挪威随机选取11万名16岁及以上人群,邀请填写问卷并提供干血斑样本,估算疫苗接种前SARS-CoV-2血清流行率。全国加权调整血清流行率为0.9%(95%CI:0.7-1.0),16-19岁组最高(1.9%),非北欧出生者1.4%,奥斯陆郡1.7%。血清流行率与病毒学检测累积发病率(0.8%)接近,提示疫情前10个月多数病例已被发现。

要点

  • 全国加权调整SARS-CoV-2血清流行率为0.9%(95%CI:0.7-1.0)。
  • 16-19岁组血清流行率最高,为1.9%(95%CI:0.9-2.9)。
  • 血清流行率(0.9%)与病毒学检测累积发病率(0.8%)比值略高于1。

核心结论

  • 挪威引入疫苗前SARS-CoV-2血清流行率较低,与病毒学检测病例数相当,提示疫情前10个月大多数病例被检测发现。
  • 研究结果提示包括接触者追踪在内的预防措施有效,人们遵守了物理距离建议,局部遏制疫情的努力至关重要。

研究设计与样本

  • 基于人群的横断面研究,于2020年11月至12月随机选取110,000名16岁及以上人群,邀请填写问卷并提供干血斑样本。
  • 应答率为30%(31,458/104,637),干血斑样本返还依从率为88%(27,700/31,458)。

主要发现

  • 全国加权调整血清流行率为0.9%(95%CI:0.7-1.0)。
  • 16-19岁年龄组血清流行率为1.9%(95%CI:0.9-2.9)。
  • 非北欧国家出生者血清流行率为1.4%(95%CI:1.0-1.9)。
  • 奥斯陆郡血清流行率为1.7%(95%CI:1.2-2.2),Vestland郡为1.4%(95%CI:0.9-1.8)。
  • 截至2020年12月中旬,SARS-CoV-2血清流行率(0.9%)与病毒学检测累积发病率(0.8%)的比值略高于1。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BackgroundSince March 2020, 440 million people worldwide have been diagnosed with COVID-19, but the true number of infections with SARS-CoV-2 is higher. SARS-CoV-2 antibody seroprevalence can add crucial epidemiological information about population infection dynamics.AimTo provide a large population-based SARS-CoV-2 seroprevalence survey from Norway; we estimated SARS-CoV-2 seroprevalence before introduction of vaccines and described its distribution across demographic groups.MethodsIn this population-based cross-sectional study, a total of 110,000 people aged 16 years or older were randomly selected during November-December 2020 and invited to complete a questionnaire and provide a dried blood spot (DBS) sample.ResultsThe response rate was 30% (31,458/104,637); compliance rate for return of DBS samples was 88% (27,700/31,458). National weighted and adjusted seroprevalence was 0.9% (95% CI (confidence interval): 0.7-1.0). Seroprevalence was highest among those aged 16-19 years (1.9%; 95% CI: 0.9-2.9), those born outside the Nordic countries 1.4% (95% CI: 1.0-1.9), and in the counties of Oslo 1.7% (95% CI: 1.2-2.2) and Vestland 1.4% (95% CI: 0.9-1.8). The ratio of SARS-CoV-2 seroprevalence (0.9%) to cumulative incidence of virologically detected cases by mid-December 2020 (0.8%) was slightly above one. SARS-CoV-2 seroprevalence was low before introduction of vaccines in Norway and was comparable to virologically detected cases, indicating that most cases in the first 10 months of the pandemic were detected.ConclusionFindings suggest that preventive measures including contact tracing have been effective, people complied with physical distancing recommendations, and local efforts to contain outbreaks have been essential.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Anda EE, Braaten T, Borch KB, et al. Seroprevalence of antibodies against SARS-CoV-2 in the adult population during the pre-vaccination period, Norway, winter 2020/21. Euro Surveill. 2022. PMID: 35362405. doi:10.2807/1560-7917.ES.2022.27.13.2100376

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。